Research

Ligand's Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential

4 monthes ago   |   By Xconomy

Ligand Pharmaceuticals is adding neurological disease and cystic fibrosis programs to its pipeline through a deal to acquire assets from drug discovery company Icagen. San Diego-based Ligand is paying $15 million up front for the “core assets” of Icagen's Durham, NC operations. The neuroscience program is being developed under a partnership with Roche while the cystic fibrosis research is a collaboration with the Cystic Fibrosis Foundation. The transaction also includes six unpartnered Icagen programs. Under the deal terms, Icagen stands to gain up to $25 million more depending on whether...
Read more ...

 


Search by Tags

   Research      Pharmaceutical      Drugs      Neurology      Discovery      Drug      Neurosciences      Neuroscience      Pharmaceuticals      National blog main      Raleigh-Durham blog main      Raleigh-Durham top stories      San Diego      San Diego blog main      San Diego top stories      Astellas      Biotech      Bristol-myers Squibb      Cystic Fibrosis      Cystic Fibrosis Foundation      Deals      Drug discovery      Icagen      Ion channels      Life Sciences      Ligand Pharmaceuticals      Pfizer      Roche      Vernalis  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

Foghorn Therapeutics could receive up to $425 million in the development deal with Merck, its first partnership with a major biopharma. One way that a cell regulates which... Read more ...

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based... Read more ...

Data Migration: Being Prepared

Data Migration: Being Prepared

Our Professional Services Written by: Alan Pham, Business Development Associate In a world where our data is crucial to our everyday lives, implementing new platforms is... Read more ...

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

The first drug for neurofibromatosis type 1 is available to patients following the FDA's approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection... Read more ...

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has... Read more ...

Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing

Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing

By early September Biogen-plus the many scientists, patients, and investors following the saga of its controversial Alzheimer's drug aducanamab-should know whether the FDA... Read more ...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period

The 2020 National Xconomy Awards - celebrating the best in biotech innovation and entrepreneurship - just got bigger! We're excited to announce the expansion of the 2020... Read more ...

Scientists Dive Deep Into Hidden World of Quantum States

Scientists Dive Deep Into Hidden World of Quantum States

Right: Animation of a Van Hove singularity shown approximately 1 nanometer below the surface of an oxide heterostructure made of atomically thin layers of strontium titanate... Read more ...

UFGI Publication round-up week 7/6/20

Manipulation of sensory characteristics and volatile compounds in strawberry fruit through the use of isolated wavelengths of light. Campbell SM, Sims CA, Bartoshuk LM... Read more ...

DNA Chisel, a versatile sequence optimizer

AbstractMotivationAccounting for biological and practical requirements in DNA sequence design often results in challenging optimization problems. Current software solutions are... Read more ...